Skip to main content


BARDA and JPEO-CBRND establish partnership with Becton Dickinson to expand domestic manufacturing capacity for needles and syringes

BARDA Response

BARDA and the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) established a Technology Investment Agreement with BD (Becton, Dickinson and Co.) to expand BD’s capacity to manufacture safety needles and syringes at facilities in Nebraska.

With this agreement, BARDA, JPEO-CBRND and BD are taking steps to increase our ability to produce safety needles and syringes in the U.S., thereby reducing dependence on other countries to provide these lifesaving supplies. This expansion is even more critical during the COVID-19 pandemic as existing supplies are used in routine healthcare and to treat the surge of COVID-19 patients.

HHS and DoD are working together as part of Operation Warp Speed to ensure the availability of needles and syringes. This effort supports significant expansion of BD’s domestic manufacturing capacity within 12 months of award. Once the capacity to produce at least 300 million safety needles and syringe units per year is achieved, the U.S. government’s private sector partners will receive priority in purchasing syringes and needles for COVID-19 medical countermeasures, including vaccines.

This award is one component of BARDA’s rapidly expanding COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.

About BD:
The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. www.bd.com.

Last Updated: July 09, 2020
Website Refresh - www.medicalcountermeasures.gov is pleased to announce a phased launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience. Over the next several months you will see differences throughout the site while we continue implementing updates. Thank you for your understanding and please let us know if you have any questions: techwatchinbox@hhs.gov